WASHINGTON, D.C. — United States pharmaceutical giant Gilead said on Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its human immunodeficiency virus (HIV) prevention medicine in lower-income countries.
The announcement comes shortly after Gilead faced pressure to open lenacapavir to a patent pool that would allow generics to be sold under license in those countries.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.